Floatz Rating
CC41/100
Confidence
Indicative
Sponsor
RenJi Hospital
Modality
UNKNOWN
Development Phase
Phase 1
Status
Active
Evidence ledger · v0.2
Clinical Evidence
Clinical track record: trial progression, reported outcomes, safety signals, and endpoint quality.
28Moderate confidence
Detailed axis rationale is planned and will be published soon.
| Trial | Phase | Status | N | Primary endpoint | Readout |
|---|---|---|---|---|---|
NCT06567080CT.gov JWCAR201 for the Treatment of Hematology Malignancy and Autoimmune Diseases | — | Not Yet Recruiting | — | — | — |
Competitive Position
Competitive setting: how crowded the indication is, class-level failures, and timing against rivals.
81High confidence
Detailed axis rationale is planned and will be published soon.
Same indication · Autoimmune Disease
| Asset | Sponsor | Phase | Rating |
|---|---|---|---|
| Jwcar201 (this asset) | RenJi Hospital | P1 | CC · 41 |
| Ursodeoxycholic Acid | West China Hospital | P4 | BB |
| Total Glucosides Of Paeony | West China Hospital | P4 | BB |
| Cyclophosphamide | The Children's Hospital of Zhejiang University School of Medicine | P2 | B |
| Cephalexin | Mayo Clinic | P4 | B |
| Cefadroxil Anhydrous | Mayo Clinic | P4 | B |
| Doxycycline | Mayo Clinic | P4 | B |
| Human Immunoglobulins | University of Cambridge | P3 | B |
| Nivestim | Johns Hopkins University | P2 | B |
+27 more in the Autoimmune Disease cohort
Other indications for Jwcar201
| Indication | Sponsor | Phase | Rating |
|---|---|---|---|
| B-Cell Neoplasm | — | P1 | CC · 43 |
| Systemic Lupus Erythematosus | — | P1 | CC · 43 |
| Diffuse Large B-Cell Lymphoma | — | P1 | C · 39 |
Scientific Foundation
Strength of the underlying biology: target validation, tractability, modality fit, and how related mechanisms have fared.
NR
Planned for methodology v0.2.
Development Feasibility
How realistically the program can be executed, drawing on modality precedent, enrollment dynamics, and sponsor delivery.
NR
Planned for methodology v0.2.
Commercial Opportunity
Commercial prize: addressable population, unmet need, and the value case for the indication.
NR
Planned for methodology v0.2.
IP & Exclusivity
Exclusivity position, covering patent protection and freedom-to-operate runway.
NR
Planned for methodology v0.2.
Manufacturing & Supply
Manufacturing and supply readiness, driven by modality process and scale-up risk.
NR
Planned for methodology v0.2.
Related assets
Citation
Floatz Terminal. Jwcar201 in Autoimmune Disease. Methodology v0.2. Rated under v0.2 effective July 8, 2026. Last refreshed July 8, 2026. Accessed July 14, 2026. https://terminal.floatz.ai/assets/jwcar201-autoimmune-disease
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →